Table 1.
Median age in years (range) | 63 (35–81) |
Sex (male-to-female ratio) | 34:6 |
Histology (adeno-to-squamous ratio) | 36:4 |
Neoadjuvant chemotherapy advised | 32 (80%)* |
Pathological T stage: | |
T0 | 1 (2.5%) |
T1 | 10 (25%) |
T2 | 9 (23%)† |
T3 | 16 (40%) |
T4 | 4 (10%) |
Pathological stage N1 | 22 (55%) |
Hospital mortality | 1 (2.5%) |
Respiratory complications | 9 (23%) |
Clinically significant anastomotic leak | 2 (5%) |
Return to theatre | 1 (2.5%) |
Median length of hospital stay in days (range) | 15 (10–91) |
Two patients (pT3N1 and pT3N0) declined neoadjuvant chemotherapy.
One pT2N0 patient died in hospital.